Who we are
Personalized Health and Related Technologies (PHRT) is a strategic focus area of the ETH Domain; the latter embracing key research institutions like ETHZ, EPFL, PSI, EMPA, Eawag and WSL. PHRT’s goals include improving the quality of Personalized Health and Precision Medicine by providing a choice of individual therapeutic strategies for patients.
In Switzerland, a number of national and international programs have committed themselves to the goal of personalized medicine. These include the strategic focus area PHRT of the ETH Domain and the SPHN initiative (Swiss Personalized Health Network) of the Swiss Academy of Medical Sciences. The two programs complement each other and coordinate their activities in order to promote Personalized Health and Personalized Medicine, in Switzerland.
What we do
Through calls for proposals, PHRT funds interdisciplinary projects in education (doctoral and postdoc level), technology translation and research in order to foster the development of Precision Medicine and health research. PHRT connects hospitals and the institutions that make up the ETH Domain so that they can share and use health data across Switzerland.
January 26, 2023, Zurich
Hope for patients with a severe rare disease
New research offers potential benefits for those affected by the hereditary metabolic disease methylmalonic aciduria. By combining the results of multiple molecular analyses, scientists can better diagnose this rare and severe disease. In the future, an improved understanding of the disease might also improve treatment options.
Methylmalonic aciduria (MMA) is a metabolic disorder that affects approximately one in 90,000 newborns; both parents must carry a genetic predisposition to the disease. This means the disease is rare. The consequences are also severe: an enzyme these young patients need for energy metabolism is left defective. As a result, a specific metabolite, which is usually broken down to create energy, instead accumulates in the body doing damage. MMA is considered incurable. While doctors can offer a certain degree of help, patients may experience delayed growth, kidney failure, and severe neurological impairment. Affected children and adolescents often use wheelchairs and do not always survive to reach adulthood.
Network brings success
The University Children’s Hospital Zurich is one of the leading global centers for diagnosing and treating this disease. Patient samples from all over the world are sent to Zurich for diagnosis. In a large interdisciplinary project, scientist from various Swiss research institutions studied 210 biopsies in detail. They examined not only all of the genes (DNA) in the patient’s cells but also the RNA transcripts of these genes and many of the proteins.
This is the first time that MMA has been studied using a multi-omics approach (genomics, transcriptomics, proteomics, metabolomics). The work was initiated and funded by the ETH domain strategic focus area Personalized Health and Related Technologies (external pagePHRTcall_made) and involved researchers from the University Children’s Hospital Zurich, ETH Zurich, EPFL, the University of Zurich, and the Health 2030 Genome Center in Geneva. The molecular analysis was carried out at PHRT’s Swiss Multi-Omics Center (SMOC) in Zurich.
Increased diagnosis accuracy
Until now, physicians have relied mainly on DNA sequencing for genetic diagnosis of MMA. However, this approach has led to repeated instances of the correct diagnosis being overlooked, reports Sean Froese, research group leader at the University Children’s Hospital Zurich and co-senior author of the study. Previous efforts have reported that only one-third to one-half of all cases can be correctly diagnosed in this way. “The reason is that everyone, even healthy individuals, has many naturally occurring genetic mutations that have no apparent impact on human health, so it’s tough to find the one or two that actually cause disease,” says Bernd Wollscheid, professor at the Department of Health Sciences and Technology at ETH Zurich, head of the Executive Committee of PHRT and co-author of the study.
By opting to expand significantly their molecular investigation, the researchers considered not only the disease’s genetic cause but also its consequences in terms of RNA, proteins, and protein function. This enabled the consortium, as part of this study, to develop a diagnostic strategy that correctly diagnosed 84 percent of the patients examined. “Moving forward, our new method will drastically increase the chances for patients to receive a correct diagnosis,” says Patrick Forny, senior physician at the University Children’s Hospital Zurich and co-lead author of the study. “This will allow the provision of the correct treatment at a much earlier stage.”
New approach to therapy
The multi-omics data also showed that MMA patients use an alternative energy source to help deal with the fact that a vital enzyme is defective. However, in patients, this alternative energy source usually is not able to sufficiently compensate for energy production lost. In in vitro experiments with patient cells, the researchers succeeded in boosting energy production to near-normal levels by supplying such an alternative energy source.
Future investigations will show if such an approach will have the same effect in animal models and can result in a feasible therapy for patients. In addition, the researchers launched a new national interdisciplinary and interinstitutional project called SwissPedHealth, co-funded by PHRT and the Swiss Personalized Health Network (SPHN), to increase the diagnostic effectiveness further and to extend the multi-omics approach to other genetic diseases.
Forny P, Bonilla X, Lamparter D, Shao W, Plessl T, Frei C, Bingisser A, Goetze S, van Drogen A, Harshman K, Pedrioli PGA, Howald C, Poms M, Traversi F, Buerer C, Cherkaoui S, Morscher RJ, Simmons L, Forny M, Ioannis Xenarios, Aebersold R, Zamboni N, Rätsch G, Dermitzakis E, Wollscheid B, Matthias R. Baumgartner MR, Froese DS: Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiency. Nature Metabolism, 26 January 2023, doi: external page10.1038/s42255-022-00720-8
November 25, 2022, Zurich
Job Openings: Personalized Data Analysis Hub
As joint venture, PHRT and SDSC are launching the Personalized Health Data Analysis Hub to support data analysis for multi-omic platforms.